Table 2

Reasons for discontinuation within the first year of treatment

Adalimumab (n=94) No (%)Infliximab (n=83) No (%)Etanercept (n=14) No (%)Total (n=191) No (%)
*Other reasons for discontinuation were pregnancy wish and patient initiative.
Inefficacy10 (11)8 (10)1 (7)19 (10)
Adverse events10 (11)20 (24)1 (7)31 (16)
Combination1 (1)5 (6)0 (0)6 (3)
Other*3 (3)2 (2)2 (14)7 (4)
Total24 (26)35 (42)4 (29)63 (33)